| Symbol | SYRE |
|---|---|
| Name | SPYRE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 805 LAS CIMAS PARKWAY,SUITE 100, AUSTIN, Texas, 78746, United States |
| Telephone | +1 512 942-2935 |
| Fax | — |
| — | |
| Website | https://www.spyre.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001636282 |
| Description | Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Additional info from NASDAQ: |
2026-07-03 01:33
Burrows Scott L 🟡 adjusted position in 7.5K shares (1 derivative) of Spyre Therapeutics, Inc. (SYRE) at $88.37 Transaction Date: Jul 01, 2026 | Filing ID: 000088
Read more
2026-07-03 01:33
Sloan Sheldon 🟡 adjusted position in 8.3K shares (1 derivative) of Spyre Therapeutics, Inc. (SYRE) at $88.34 ($1.2M) Transaction Date: Jul 01, 2026 | Filing ID: 000087
Read more
2026-07-03 01:32
Director Turtle Cameron 🔴 sold 15.0K shares of Spyre Therapeutics, Inc. (SYRE) at $88.91 ($1.3M) Transaction Date: Jul 01, 2026 | Filing ID: 000086
Read more
2026-07-01 21:02
📋 CAMERON TURTLE (Director) plans to sell 45K shares of SPYRE THERAPEUTICS INC (at $88.78 each, total $4.0M) Filed: Jul 01, 2026 | ID: 006779
Read more
2026-06-27 01:31
Burrows Scott L 🟡 adjusted position in 15.0K shares (1 derivative) of Spyre Therapeutics, Inc. (SYRE) at $87.14 ($1.7M) Transaction Date: Jun 25, 2026 | Filing ID: 000008
Read more
2026-06-25 20:03
📋 SCOTT BURROWS (Officer) plans to sell 15K shares of SPYRE THERAPEUTICS, INC. (at $87.13 each, total $1.3M) Filed: Jun 25, 2026 | ID: 006485
Read more
2026-06-24 01:57
📋 Fairmount Healthcare Fund II L.P. (Director) plans to sell 4.7M shares of Spyre Therapeutics, Inc. (at $85.31 each, total $399.7M) Filed: Jun 23, 2026 | ID: 076969
Read more
2026-06-24 01:56
Director Fairmount Funds Management LLC 🟡 adjusted position in 18.5M shares (2 derivative) of Spyre Therapeutics, Inc. (SYRE) at $85.31 ($399.7M) Transaction Date: Jun 23, 2026 | Filing ID: 076967
Read more
2026-06-24 01:32
Director HENDERSON MICHAEL THOMAS 🔴 sold 20.0K shares of Spyre Therapeutics, Inc. (SYRE) at $100.00 ($2.0M) Transaction Date: Jun 22, 2026 | Filing ID: 000084
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07652294 | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in C… | Phase2 | Ulcerative Colitis | Enrolling_By_Invitation | 2026-06-08 | 2030-01-03 | ClinicalTrials.gov |
| NCT07148414 | A Study of SPY072 in Rheumatic Disease | Phase2 | Rheumatoid Arthritis | Active_Not_Recruiting | 2025-08-21 | 2028-03-31 | ClinicalTrials.gov |
| NCT07012395 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Sev… | Phase2 | Ulcerative Colitis | Recruiting | 2025-05-27 | 2028-03-01 | ClinicalTrials.gov |
| NCT06873724 | A Study of SPY003-207 in Healthy Volunteers | Phase1 | Healthy | Active_Not_Recruiting | 2025-03-10 | 2026-11-18 | ClinicalTrials.gov |
| NCT06672718 | A Study of SPY002-091 in Healthy Volunteers | Phase1 | Healthy | Active_Not_Recruiting | 2024-11-26 | 2026-08-19 | ClinicalTrials.gov |
| NCT06622070 | A Study of SPY002-072 in Healthy Volunteers | Phase1 | Healthy | Recruiting | 2024-11-18 | 2026-08-08 | ClinicalTrials.gov |
| NCT06448247 | A Study of SPY001-001 in Healthy Volunteers | Phase1 | Healthy | Completed | 2024-06-06 | 2026-03-10 | ClinicalTrials.gov |
Total clinical trials: 7
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| Placebo | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06672718 |
| SPY002-091 | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06672718 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06622070 |
| SPY002-072 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06622070 |
| Placebo | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06672718 |
| SPY002-091 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06672718 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06873724 |
| SPY003-207 | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06873724 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06448247 |
| SPY001-001 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06448247 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | DRUG | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | DRUG | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | DRUG | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003-207 | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06873724 |
| SPY002-091 | DRUG | Phase PHASE1 | Healthy | RECRUITING | NCT06672718 |
| SPY002-072 | DRUG | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | DRUG | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY001-001 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06448247 |
Total products: 297